Evaluation of Adjuvant Treatments for T1 N0 M0 Triple-Negative Breast Cancer

JAMA Network Open
Zhen ZhaiZhijun Dai

Abstract

Adjuvant chemotherapy remains the only recommended treatment for patients with triple-negative breast cancer (TNBC). However, the existing evidence is not enough to recommend adjuvant therapies to patients with T1 N0 M0 TNBC. To evaluate the association of different adjuvant therapies with survival outcome in patients with T1 N0 M0 TNBC stratified by cancer stage and age. Postoperative patients diagnosed as having T1 N0 M0 TNBC between 2010 and 2015 who were enrolled in the Surveillance, Epidemiology, and End Results cancer registry program were included in this population-based cohort study. Data analysis was performed from March 27, 2019, to August 10, 2020. Chemotherapy and radiotherapy. Kaplan-Meier curve and univariate and multivariable Cox proportional hazards regression analyses were performed to compare overall survival (OS) and breast cancer-specific survival (BCSS) between the different treatments. A cohort of 7739 eligible patients (mean [SD] age, 59.5 [12.4] years; all female) were included in the present study. The 5-year OS of the total patients was 91.7% (95% CI, 90.9%-92.5%), and median follow-up was 45 months (95% CI, 44-46 months). Patients aged 70 years and older or with T1a TNBC were more likely to receive a...Continue Reading

References

Jan 5, 2002·Journal of the National Cancer Institute. Monographs·A GoldhirschA S Coates
Aug 13, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christine BouchardyGeorges Vlastos
Nov 3, 2009·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·K-J WinzerUNKNOWN German Breast Cancer Study Group (GBSG)
Feb 25, 2010·Annals of Surgical Oncology·Stephen B Edge, Carolyn C Compton
Apr 28, 2011·Cancer·Nancy BreenJeannine S Schiller
Jan 29, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Debora de Melo GagliatoMariana Chavez-Macgregor
Jun 4, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ines Vaz-LuisNancy U Lin
Oct 13, 2016·The New England Journal of Medicine·H Gilbert WelchBarnett S Kramer
Apr 12, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Joanne L BlumNorman Wolmark
Jun 25, 2017·The Breast : Official Journal of the European Society of Mastology·Waqar HaqueSandra Hatch
Jul 10, 2017·Breast Cancer Research and Treatment·Carol A Parise, Vincent Caggiano
Aug 2, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Martin SjöströmPer Karlsson
Aug 7, 2017·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·A de NonnevilleG Houvenaeghel
Sep 16, 2017·Breast Cancer Research and Treatment·Roberto A Leon-FerreMatthew P Goetz
Apr 16, 2018·Current Treatment Options in Oncology·Priyanka Sharma
Sep 4, 2018·The Breast : Official Journal of the European Society of Mastology·Åsa WickbergGöran Liljegren
Oct 9, 2018·Critical Reviews in Oncology/hematology·Ming Yuan HeNicolas Magné
Dec 12, 2018·The Breast : Official Journal of the European Society of Mastology·Yi-Xing RenZhi-Ming Shao

❮ Previous
Next ❯

Methods Mentioned

BETA
dissection

Software Mentioned

SEER
R
R Project for Statistical Computing
Stat

Related Concepts

Related Feeds

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.